No Association of Plasma Prothrombin Concentration or the G20210A Mutation with Incident Cardiovascular Disease

Adam M. Smiles; Nancy S. Jenny; Zhonghua Tang; Alice Arnold; Mary Cushman; Russell P. Tracy

doi:10.1055/s-0037-1613057

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2002; 87(04): 614-621
DOI: 10.1055/s-0037-1613057

Review Article

Schattauer GmbH

No Association of Plasma Prothrombin Concentration or the G20210A Mutation with Incident Cardiovascular Disease

Results from the Cardiovascular Health Study

Adam M. Smiles

¹Department of Pathology, College of Medicine, University of Vermont, Burlington, VT

,

Nancy S. Jenny

¹Department of Pathology, College of Medicine, University of Vermont, Burlington, VT

,

Zhonghua Tang

¹Department of Pathology, College of Medicine, University of Vermont, Burlington, VT

,

Alice Arnold

²Department of Biostatistics, University of Washington, Seattle, WA

,

Mary Cushman

¹Department of Pathology, College of Medicine, University of Vermont, Burlington, VT

³Department of Medicine, College of Medicine, University of Vermont, Burlington, VT

,

Russell P. Tracy

¹Department of Pathology, College of Medicine, University of Vermont, Burlington, VT

⁴Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT, USA

› Author Affiliations

Abstract

Summary

Prothrombin is a key factor in blood clotting, a process intimately involved in thrombotic disease. We assessed prothrombin levels and G20210A genotype in a case-control study within the Cardiovascular Health Study. Cases included angina, myocardial infarction, stroke, and the presence of MRI-detectable infarcts (n ≈ 250 each). Populationbased controls free of clinical cardiovascular disease (CVD) (n ≈ 500) and a subset free of clinical and subclinical CVD (n ≈ 250) were used for comparison. The 20210 A allele, frequency 2.9%, was associated with higher mean prothrombin levels: 166.3 vs. 139.5 µg/ml (P <0.001). Significant correlates of prothrombin included gender, plasma lipids, other vitamin K-dependent proteins, and inflammatory markers, but not race, smoking, hypertension, diabetes, measures of subclinical CVD, or markers of procoagulant activity. Compared to controls, neither genotype nor prothrombin level was associated with any CVD case group. We conclude that, in the elderly, neither prothrombin level nor 20210 genotype were associated with either CVD risk factors or events. This is consistent with the lack of association of prothrombin levels with measures of underlying CVD or procoagulant markers.

Keywords

Prothrombin - elderly - nested case-control study - genetic polymorphism - cardiovascular disease

Full Text

References

References
1 Poort S, Rosendaal F, Reitsma P, Bertina R. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
2 Ferraresi P, Marchetti G, Legnani E, Cavallari E, Castoldi E, Mascoli F, Ardissino D, Palareti G, Bernardi F. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vasc Biol 1997; 17: 2418-22.
3 Cumming A, Keeney S, Salden A, Bhavnani M, Shwe K, Hay C. The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population. Br J Haematol 1997; 98: 353-5.
4 Hillarp A, Zoller B, Svensson P, Dahlback B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost 1997; 78: 990-2.
5 Kapur R, Mills L, Spitzer S, Hultin M. A prothrombin gene mutation is significantly associated with venous thrombosis. Arterioscler Thromb Vasc Biol 1997; 17: 2875-9.
6 Arruda V, Annichino-Bizzacchi J, Goncalves M, Costa F. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost 1997; 78: 1430-3.
7 Arruda V, Siquiera L, Chiaparini L, Coelho O, Mansur A, Ramires A, Annichino-Bizzacchi J. Prevalence of the prothrombin gene variant 20210 G->A among patients with myocardial infarction. Cardiovasc Res 1998; 37: 42-5.
8 De Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Rossi E, Molinari M, Servidei S, Tonali P, Leone G. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 1998; 91: 3562-5.
9 Rosendaal F, Siscovick D, Schwartz S, Psaty B, Raghunathan T, Vos H. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997; 90: 1747-50.
10 Corral J, Gonzalez-Conejero R, Lozano M, Rivera J, Heras I, Vicente V. The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial disease. Br J Haematol 1997; 99: 304-7.
11 Longstreth W, Rosendaal F, Siscovick D, Vos H, Schwartz S, Psaty B, Raghunathan T, Koepsell T, Reitsma P. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke 1998; 29: 577-80.
12 Reuner K, Ruf A, Grau A, Rickmann H, Stolz E, Juttler E, Druschky K, Patscheke H. Prothrombin Gene G20210->A transition is a risk factor for cerebral vein thrombosis. Stroke 1998; 29: 1765-9.
13 Doggen C, Manger VCats, Bertina R, Rosendaal F. Interaction of coagulation defects and cardiovascular risk factors. Circulation 1998; 97: 1037-41.
14 Watzke H, Schuttrumpf J, Graf S, Huber K, Panzer S. Increased prevalence of a polymorphism in the gene coding for human prothrombin in patients with coronary heart disease. Thromb Res 1997; 87: 521-6.
15 Ridker P, Hennekens C, Miletich J. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999; 99: 999-1004.
16 Franco R, Trip M, ten Cate H, van den Ende A, Prins M, Kastelein J, Reitsma P. The 20210 G->A mutation in the 3’-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Br J Haematol 1999; 104: 50-4.
17 Eikelboom J, Baker R, Parsons R, Taylor R, van Bockxmeer F. No association between the 20210 G/A prothrombin gene mutation and premature coronary artery disease. Thromb Haemost 1998; 80: 878-80.
18 Simioni P, Tormene D, Manfrin D, Gavasso S, Luni S, Stocco D. Girolami Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. Br J Haematol 1998; 103: 1045-50.
19 Hoffman C, Lawson W, Miller R, Hultin M. Correlation of vitamin Kdependent clotting factors with cholesterol and triglycerides in healthy young adults. Arterioscler Thromb 1994; 14: 1737-40.
20 Tracy R, Losito R, Howard P, Cushman M, Bovill E. The association of plasma lipids and vitamin K-dependent coagulation factors. In: Nutrition, genetics and heart disease. Vol. 6. Bray G, Ryan D. eds. Pennington Center Nutrition Series. Baton Rouge: LSU Press; 1996: 29-49.
21 National Center for Health Statistics. Advance report of final mortality statistics, 1987. Public Health Service; Hyattsville, MD: 1989
22 Fried L, Borhani N, Enright P, Furberg C, Gardin J, Kronmal R, Kuller L, Manolio T, Mittelmark M, Newman A, O’Leary D, Psaty B, Rautaharju P, Tracy R, Weiler P. for the CHS Research Group. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991; 01: 263-76.
23 Tell G, Fried L, Hermanson B, Manolio T, Newman A, Borhani N. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol 1993; 03: 358-66.
24 Cushman M, Cornell E, Howard P, Bovill E, Tracy R. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 1995; 41: 264-70.
25 Gardin J, Wong N, Bommer W, Klopfenstein H, Smith V, Tabatznik B, Siscovick D, Lobodzinski S, Anton-Culver H, Manolio T. Echocardiographic design of a multi-center investigation of free-living elderly subjects: the Cardiovascular Health Study. J Am Soc Echocardiography 1992; 05: 63-72.
26 Newman A, Siscovick D, Manolio T, Polak J, Fried L, Borhani N, Wolfson S. for the CHS Investigators. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Circulation 1993; 88: 837-45.
27 O’Leary D, Polak J, Wolfson S, Bond M, Bommer W, Sheth S, Psaty B, Sharrett A, Manolio T. for CHS Investigators. Use of sonography to evaluate carotid atherosclerosis in the elderly: the Cardiovascular Health Study. Stroke 1991; 22: 1155-63.
28 Bryan RNWS, Mill T, Elster A, Jungreis C, Poirier V, Lind B, Manolio T. Infarctlike lesions in the brain: prevalence and anatomic characteristics at MR imaging of the elderly: data from the Cardiovascular Health Study. Radiology 1997; 202: 17-19.
29 Ives D, Fitzpatrick A, Bild D, Psaty B, Kuller L, Crowley P, Cruise R, Theroux S. Surveillance and ascertainment of cardiovascular events. Ann Epidemiol 1995; 05: 278-85.
30 Cushman M, Psaty B, Macy E, Bovill E, Cornell E, Kuller L, Tracy R. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. Arterioscler Thromb Vasc Biol 1996; 16: 1163-9.
31 American Diabetes Association. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 07: 1183-97.
32 Furberg C, Manolio T, Psaty B, Bild D, Borhani N, Newman A, Tabatznik B, Rautaharju P. Major electrocardiographic abnormalities in persons aged 65 years and older (the Cardiovascular Health Study). Am J Cardiol 1992; 69: 1329-35.
33 Kuller L, Shemanski L, Psaty B, Borhani N, Gardin J, Haan M, O’Leary D, Savage P, Tell G, Tracy R. Subclinical disease as an independent risk factor for cardiovascular disease. Circulation 1995; 92: 720-6.
34 Smiles A, Macy E, Sakkinen P, Bovill E, Mann K, Tracy R. Biological and analytical variability in plasma prothrombin concentration: implications for use in epidemiology. Blood Coagul Fibrinolysis 1998; 09: 525-31.
35 Bajaj M, Rana S, Wysolmerski R, Bajaj S. Inhibitor of the VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with hepatocellular disease. J Clin Invest 1987; 79: 1874-8.
36 Rosenberg R. Chemistry of the hemostatic mechanism and its relationship to the action of heparin. Fed Proc 1977; 36: 10-18.
37 Howard P, Bovill E, Mann K, Tracy R. A monoclonal antibody-based immunoassay for measurement of protein C in plasma. Clin Chem 1988; 34: 324-30.
38 Bovill E, Landesman M, Busch S, Fregeau G, Mann K, Tracy R. Studies on the measurement of protein S in plasma. Clin Chem 1991; 37: 1708-14.
39 Declerck P, Mombaerts P, Holvoet P, De Mol M, Collen D. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis. Thromb Haemost 1987; 58: 1024-9.
40 Diagnostica Stago. ST4 Operator’s Manual. Parsippany, NJ: American Bioproducts; 1992
41 Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemost 1985; 54: 684-97.
42 DeClerck P, Alessi M, Verstreken M, Kruithof E, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 (PAI-1) in biological fluids with a murine monoclonal antibody based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-5.
43 Declerck P, Collen D. Measurement of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzyme-linked immunosorbent assays. Thromb Res. 1990 (suppl X) 3-9.
44 Holvoet P, de Boer A, Verstreken M, Collen D. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-alpha-2-antiplasmin complex in human plasma – application to the detection of in vivo activation of the fibrinolytic system. Thromb Haemost 1986; 56: 124-7.
45 Alessi M, Juhan-Vague I, Declerck P, Anfosso F, Gueunoun E, Collen D. Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels. Thromb Res 1990; 60: 509-16.
46 Kuller L, Tracy R, Shaten J, Meilahn E. for the MRFIT Research Group. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 144: 537-47.
47 Howard P, Bovill E, Pike J, Church W, Tracy R. Factor VII antigen levels in a healthy blood donor population. Thromb Haemost 1994; 72: 21-7.
48 SPSS for Windows Base 10.0. Chicago, SPSS, Inc. Chicago, IL: SPSS, Inc; 1999
49 Kuller L, Fisher L, McClelland R, Fried L, Cushman M, Jackson S, Manolio T. Differences in prevalence of and risk factors for subclinical vascular disease among black and white participants in the cardiovascular health study. Arterioscler Thromb Vasc Biol 1998; 18: 283-93.
50 Moyer M, Tracy R, Tracy P, van’t Veer C, Sparks C, Mann K. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler Thromb Vasc Biol 1998; 18: 458-65.
51 Cushman M, Yanez D, Psaty B, Fried L, Heiss G, Lee M, Polak J, Savage P, Tracy R. for the CHS Investigators. Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study. Amer J Epidemiol 1996; 143: 665-76.
52 Folsom A, Wu K, Davis C, Conlan M, Sorlie P, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191-205.
53 Kyrle P, Mannhalter C, Beguin S, Stumpflen A, Hirschl M, Weltermann A, Stain M, Brenner B, Speiser W, Pabinger I, Lechner K, Eichinger S. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 1998; 18: 1287-91.